Anzeige
❌
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A12DEH | ISIN: CH0256379097 | Ticker-Symbol: 6ML
Lang & Schwarz
21.01.25
13:22 Uhr
4,975 Euro
-0,093
-1,83 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG 5-Tage-Chart
RealtimeGeldBriefZeit
4,9405,01013:23

Aktuelle News zur MOLECULAR PARTNERS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.01.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer1SEC Filings
13.01.Molecular Partners und Orano dehnen Kooperation weiter aus2punkt4.info
13.01.Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer3Seeking Alpha
13.01.Molecular Partners erweitert Zusammenarbeit mit Orano und gibt Forschungs-Update6cash
12.01.Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer324GlobeNewswire (Europe)New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties'...
► Artikel lesen
12.01.Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference392GlobeNewswire (Europe)Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano...
► Artikel lesen
MOLECULAR PARTNERS Aktie jetzt für 0€ handeln
17.12.24Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January392GlobeNewswire (Europe)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
08.12.24Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024353GlobeNewswire (Europe)MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...
► Artikel lesen
07.11.24Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024361GlobeNewswire (Europe)Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317's ability to activate CD40 in a...
► Artikel lesen
05.11.24Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition298GlobeNewswire (Europe)Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin...
► Artikel lesen
31.10.24Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going391GlobeNewswire (Europe)Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...
► Artikel lesen
31.10.24MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer5SEC Filings
25.10.24Molecular Partners legt Preis für Aktienangebot in den USA fest9punkt4.info
25.10.24Molecular Partners prices $20M offering2Seeking Alpha
25.10.24Molecular Partners Announces Pricing of $20 Million Underwritten Offering313GlobeNewswire (Europe)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
22.10.24Molecular Partners stock climbs 6% on expanded radiopharmaceuticals deal3Seeking Alpha
22.10.24MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3SEC Filings
22.10.24Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024303GlobeNewswire (Europe)Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision...
► Artikel lesen
22.10.24Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics310GlobeNewswire (Europe)Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold...
► Artikel lesen
07.10.24Molecular Partners-Aktien steigen nach Outperform-Bewertung von Leerink24Investing.com Deutsch
Seite:  1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1